Ben Kaminow

Physical priors improve performance of structure-based binding affinity models

Structure-based drug discovery is a widely used paradigm for the rational design of novel small molecule therapeutics. However, the benefits conferred by the use of structural information has seen limited adoption in machine learning, where ligand-only ("2D") models are still the industry standard for molecular propert...